JP2015520201A - Ｌｐａｒ拮抗薬としての置換ピラゾール化合物 - Google Patents

Ｌｐａｒ拮抗薬としての置換ピラゾール化合物 Download PDF

Info

Publication number
JP2015520201A
JP2015520201A JP2015517702A JP2015517702A JP2015520201A JP 2015520201 A JP2015520201 A JP 2015520201A JP 2015517702 A JP2015517702 A JP 2015517702A JP 2015517702 A JP2015517702 A JP 2015517702A JP 2015520201 A JP2015520201 A JP 2015520201A
Authority
JP
Japan
Prior art keywords
phenyl
methyl
pyrazol
acid
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517702A
Other languages
English (en)
Japanese (ja)
Inventor
ガブリエル，スティーブン・ディームズ
ハミルトン，マシュー・マイケル
チャン，イミン
シドゥリ，アチュサラオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015520201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2015520201A publication Critical patent/JP2015520201A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015517702A 2012-06-20 2013-06-17 Ｌｐａｒ拮抗薬としての置換ピラゾール化合物 Pending JP2015520201A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
US61/661,958 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
JP2015520201A true JP2015520201A (ja) 2015-07-16

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517702A Pending JP2015520201A (ja) 2012-06-20 2013-06-17 Ｌｐａｒ拮抗薬としての置換ピラゾール化合物

Country Status (22)

Country Link
US (1) US20150259295A1 (enExample)
EP (1) EP2864294A1 (enExample)
JP (1) JP2015520201A (enExample)
KR (1) KR20150011003A (enExample)
CN (1) CN104411690A (enExample)
AU (1) AU2013279510A1 (enExample)
BR (1) BR112014031108A2 (enExample)
CA (1) CA2869602A1 (enExample)
CL (1) CL2014003242A1 (enExample)
CO (1) CO7160077A2 (enExample)
CR (1) CR20140516A (enExample)
EA (1) EA201492283A1 (enExample)
HK (1) HK1206341A1 (enExample)
IL (1) IL236091A0 (enExample)
IN (1) IN2014DN09347A (enExample)
MA (1) MA37765A1 (enExample)
MX (1) MX2014014105A (enExample)
PE (1) PE20142445A1 (enExample)
PH (1) PH12014502364A1 (enExample)
SG (1) SG11201407229UA (enExample)
UA (1) UA109867C2 (enExample)
WO (1) WO2013189862A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021507895A (ja) * 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのピラゾールｎ−連結のカルバモイルシクロヘキシル酸
JP2024517016A (ja) * 2021-05-11 2024-04-18 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975235B2 (en) 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
EP2988743B1 (en) 2013-03-15 2020-12-09 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
ES2824801T3 (es) 2014-06-27 2021-05-13 Ube Industries Sal de compuesto heterocíclico sustituido con halógeno
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
KR102775995B1 (ko) 2019-11-15 2025-03-11 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4337654A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063241A1 (ja) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2013025733A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063241A1 (ja) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2013025733A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021507895A (ja) * 2017-12-19 2021-02-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのピラゾールｎ−連結のカルバモイルシクロヘキシル酸
JP7301839B2 (ja) 2017-12-19 2023-07-03 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸
JP2024517016A (ja) * 2021-05-11 2024-04-18 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
JP7701473B2 (ja) 2021-05-11 2025-07-01 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用

Also Published As

Publication number Publication date
CN104411690A (zh) 2015-03-11
BR112014031108A2 (pt) 2017-06-27
CR20140516A (es) 2014-12-01
EP2864294A1 (en) 2015-04-29
PE20142445A1 (es) 2015-01-28
PH12014502364A1 (en) 2015-01-12
CA2869602A1 (en) 2013-12-27
IL236091A0 (en) 2015-02-01
SG11201407229UA (en) 2014-12-30
UA109867C2 (ru) 2015-10-12
WO2013189862A1 (en) 2013-12-27
EA201492283A1 (ru) 2015-04-30
MA37765A1 (fr) 2017-04-28
MX2014014105A (es) 2015-03-05
IN2014DN09347A (enExample) 2015-07-17
CO7160077A2 (es) 2015-01-15
HK1206341A1 (en) 2016-01-08
CL2014003242A1 (es) 2015-03-20
KR20150011003A (ko) 2015-01-29
US20150259295A1 (en) 2015-09-17
AU2013279510A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
JP2015520201A (ja) Ｌｐａｒ拮抗薬としての置換ピラゾール化合物
US9321738B2 (en) N-alkyltriazole compounds as LPAR antagonists
TWI767410B (zh) 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途
TWI426910B (zh) Cetp抑制劑，醫藥組合物及其用途
JP2015520203A (ja) Ｌｐａｒ拮抗薬としてのｎ−アリールトリアゾール化合物
US9464098B2 (en) Substituted triazole boronic acid compounds
TW200825058A (en) Cysteine protease inhibitors
CN117295724A (zh) Lpa受体拮抗剂及其用途
JP2020532550A (ja) リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物
JP4585522B2 (ja) ブラジキニン拮抗物質又は逆作用物質としてのアルファ−ヒドロキシアミド
CA2877184A1 (en) Lpar-substituted cyanopyrazole compounds
JP2009522224A (ja) コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体
JP2007501790A (ja) スルホニル置換ｎ−（ビアリールメチル）アミノシクロプロパンカルボキサミド
JP2002212179A (ja) 新規アニリド誘導体又はその塩及びこれを含有する医薬
US7816380B2 (en) 1-hydroxycycloalkanecarboxamide derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160726